Obermatt
See Similar Stocks →

RadNet

NMQ:RDNT · US7504911022
Health Care Providers & ServicesLarge

360

14
EV / EBIT15
Price / Owner Earnings93
Owner Earnings Yield1
Dividend Yield1
Price/Sales90
EV / Gross Profit5
Price/Book40
Return on Capital34
Cash Return on Capital24
Return on Equity37
EBIT Margin45
Gross Profitability5
Accruals9
Owner Earnings Margin24
Sales growth82
Profit Growth66
Long-Term EPS Growth49
Reinvestment19
Price momentum37
Debt load19
Refinancing16
Debt Payback1
Liquidity51
Analyst ratings65
Opinion Changes50
Price Target Upside90
Market mood71
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

RadNet doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeLarge
TypePublic Company
ExchangeNASDAQGM
Founded2008
Employees2,583
Websiteradnet.com
ISINUS7504911022
Last UpdateApr 2, 2026
Indices
Artificial Intelligence & Big DataNASDAQ (USA)
Themes
Health DiagnosticsCardiovascularMachine LearningUrologyOutpatient CareOncologyArtificial IntelligenceHealth CareHospital

Description

RadNet, Inc. provides diagnostic imaging services in the United States. The company's principal business segment is the provision of diagnostic imaging services. As of December 31, 2025, the company operated, directly or indirectly through hospital…

Analysis

Weak and unloved

RadNet, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

What to watch: The financial cushion is thinner than comfortable. Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
23
2023202420252026

All-time high

32

Jan 2025

All-time low

1

Jan 2024

Average rank

15

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
90
11
36
61
Price/Earnings
1
3
6
19
Price/Book
40
15
27
19
Dividend Yield
1
1
1
1
Value (overall)
28
4
1
16

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare RadNet with its peers
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Johnson & Johnson
NYQ:JNJ
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Pliant Therapeutics
NSQ:PLRX
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Zoetis
NYQ:ZTS
56
CountryUSA
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Intellia Therapeutics
NMQ:NTLA
25
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →